These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29755451)

  • 41. A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris?
    Caldarola G; Feliciani C
    Expert Rev Clin Immunol; 2011 Mar; 7(2):187-91. PubMed ID: 21426256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins.
    Wang X; Brégégère F; Frusić-Zlotkin M; Feinmesser M; Michel B; Milner Y
    Apoptosis; 2004 Mar; 9(2):131-43. PubMed ID: 15004510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.
    Pollmann R; Schmidt T; Eming R; Hertl M
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):1-25. PubMed ID: 29313220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies.
    Stanley JR; Koulu L; Thivolet C
    J Clin Invest; 1984 Aug; 74(2):313-20. PubMed ID: 6378972
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting pemphigus autoantibodies through their heavy-chain variable region genes.
    Payne AS; Siegel DL; Stanley JR
    J Invest Dermatol; 2007 Jul; 127(7):1681-91. PubMed ID: 17392832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
    Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
    Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenic human monoclonal antibody against desmoglein 3.
    Yeh SW; Cavacini LA; Bhol KC; Lin MS; Kumar M; Duval M; Posner MR; Ahmed AR
    Clin Immunol; 2006 Jul; 120(1):68-75. PubMed ID: 16635589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pemphigus--paradigm of autoantibody-mediated autoimmunity.
    Hertl M; Veldman C
    Skin Pharmacol Appl Skin Physiol; 2001; 14(6):408-18. PubMed ID: 11598441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intraperitoneal injection of pemphigus vulgaris-IgG into mouse depletes epidermal keratinocytes of desmoglein 3 associated with generation of acantholysis.
    Shu E; Yamamoto Y; Aoyama Y; Kitajima Y
    Arch Dermatol Res; 2007 Jun; 299(3):165-7. PubMed ID: 17431647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3.
    Tsunoda K; Ota T; Aoki M; Yamada T; Nagai T; Nakagawa T; Koyasu S; Nishikawa T; Amagai M
    J Immunol; 2003 Feb; 170(4):2170-8. PubMed ID: 12574390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides.
    Dworschak J; Recke A; Freitag M; Ludwig RJ; Langenhan J; Kreuzer OJ; Zillikens D; Schmidt E
    J Dermatol Sci; 2012 Feb; 65(2):102-9. PubMed ID: 22261006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.
    Amber KT; Staropoli P; Shiman MI; Elgart GW; Hertl M
    Exp Dermatol; 2013 Nov; 22(11):699-704. PubMed ID: 24433179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris.
    Ishii K; Harada R; Matsuo I; Shirakata Y; Hashimoto K; Amagai M
    J Invest Dermatol; 2005 May; 124(5):939-46. PubMed ID: 15854034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pemphigus IgG causes skin splitting in the presence of both desmoglein 1 and desmoglein 3.
    Spindler V; Drenckhahn D; Zillikens D; Waschke J
    Am J Pathol; 2007 Sep; 171(3):906-16. PubMed ID: 17640963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokine networks in Pemphigus vulgaris: An integrated viewpoint.
    Giordano CN; Sinha AA
    Autoimmunity; 2012 Sep; 45(6):427-39. PubMed ID: 22686612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical studies identify non-apoptotic low-level caspase-3 as therapeutic target in pemphigus vulgaris.
    Luyet C; Schulze K; Sayar BS; Howald D; Müller EJ; Galichet A
    PLoS One; 2015; 10(3):e0119809. PubMed ID: 25748204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p38MAPK inhibition prevents disease in pemphigus vulgaris mice.
    Berkowitz P; Hu P; Warren S; Liu Z; Diaz LA; Rubenstein DS
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12855-60. PubMed ID: 16908851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus.
    Yoshida K; Takae Y; Saito H; Oka H; Tanikawa A; Amagai M; Nishikawa T
    J Am Acad Dermatol; 2005 May; 52(5):839-45. PubMed ID: 15858475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pemphigus vulgaris and its active disease mouse model.
    Amagai M
    Curr Dir Autoimmun; 2008; 10():167-81. PubMed ID: 18460885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pemphigus vulgaris autoimmune globulin induces Src-dependent tyrosine-phosphorylation of plakophilin 3 and its detachment from desmoglein 3.
    Cirillo N; AlShwaimi E; McCullough M; Prime SS
    Autoimmunity; 2014 Mar; 47(2):134-40. PubMed ID: 24328683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.